LLY change at the top., page-9

Prana have done a fantastic job bringing the lead MPAC through to phase3 trials only to be obstructed by the FDA. The phase 2 Reach2HD cognition results are there for HD. That result replicated some effects from the Alzheimer's trial. The Reach2HD trial passed the safety primary endpoint easily.
If you want to bash management, in hindsight, I think everybody would agree it was probably a bad mistake to go anywhere near the USA with that drug at such a critical stage of its development.
Now we need to wait for the european reaction.
X you must post for the company I guess. What do you mean fair shots at goal? Is that a 40 patient AD trial? You think being obstructed from running a phase3 after stellar safety profile proven over 8 human trials is a fair shot at goal.